Management to Host Conference Call Wednesday, October 16, at 5 p.m. ET
Expected to be immediately accretive
Adds $9.8 million of annual unaudited revenue and $3.1 million of annual unaudited adjusted EBITDA
Capital light, highly recurring revenue business in stable and growing market
Latest acquisition under the Kingsway Search Xcelerator platform
Prior Phase 3 studies showed positive benefits in increasing unstimulated whole saliva secretion Ainos aims to complete all regulatory approvals for the study in Q4 2024
Read More